Skip to content

To study the efficacy of pathyashadanga ghana vati and pathyashadanga kwatha in the management of migraine

Efficacy of Pathyashadanga Ghana Vati and Pathyashadanga Kwatha in the management of Ardhavabhedaka (Migraine) An open labelled randomized comparative clinical trial - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/05/087496
Enrollment
100
Registered
2025-05-23
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G43- Migraine

Interventions

None listed

Sponsors

Institute of Teaching and Research in Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients within the age group of 18 to 60 years, presenting with signs and symptoms of Migraine (Ardhavabhedaka) will be included in the study. 2. Participants reporting at least one migraine attack per month.

Exclusion criteria

Exclusion criteria: 1.Patients experiencing excruciating head ache during migraine attack (Patients are unable to do anything) will be excluded from the study. 2.Patients taking regular medication for migraine will be excluded from the study 3.Patients diagnosed with other primary headache (Cluster headache, Tension type head ache) 4.Diagnosed cases of Secondary head ache, Complicated Migraine like Status migrainosus, Hemiplegic migraine & Other Neurological disorders 5.Patients suffering from any chronic debilitating diseases like Tuberculosis, Asthma and other Respiratory problems. 6.Known cases of Diabetes Mellitus and uncontrolled hypertension, 7.Patients diagnosed with Referred headache, Trigeminal Neuralgia and Sinusitis 8.Patients diagnosed with Psychiatric disorders. 9.Pregnant or lactating women. 10.Patients using any other systemic drugs which may alter the results of study

Design outcomes

Secondary

MeasureTime frame
Change in Quality of life using MSQOL.Timepoint: Change in Quality of life using MSQOL on 0th and 45th day

Primary

MeasureTime frame
1. Change in signs and symptoms of migraine. 2. Change in calcitonin- gene-related peptide (CGRP) level. Timepoint: 1. Change in signs and symptoms of migraine on 0th, 8th ,15th, 22nd, 29th ,36th, 45nd 60th and 90th day of treatment 2. Change in calcitonin- gene-related peptide (CGRP) level on 0th and 45th day.

Countries

India

Contacts

Public ContactDr R S Unadkat

Institute of Teaching and Research in Ayurveda

rsunadkat@itra.edu.in9427242598

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026